Biogen (BIIB) PT Raised to $369 at Morgan Stanley
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $203.89 -1.56%
Rating Summary:
27 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 23 | New: 12
Rating Summary:
27 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 23 | New: 12
Join SI Premium – FREE
Morgan Stanley raised its price target on Biogen (NASDAQ: BIIB) to $369.00 (from $365.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bicara Therapeutics Inc (BCAX) PT Raised to $39 at BTIG
- Freedom Broker Upgrades Alico Inc. (ALCO) to Buy
- On Holding AG (ONON)PT Lowered to $42 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
